FierceBiotech 2026-01-20 Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years
FierceBiotech 2026-01-20 Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs
FierceBiotech 2026-01-20 Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis
FierceBiotech 2026-01-20 Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark
FierceBiotech 2026-01-20 GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair
FierceBiotech 2026-01-20 ARPA-H director eyes future beyond vaccines, ‘winning the biotech race’ against China
FierceBiotech 2026-01-19 FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions
FierceBiotech 2026-01-19 AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta
FierceBiotech 2026-01-19 Immunology biotech Agomab, eye-focused SpyGlass are latest biotechs to share IPO ambitions
FierceBiotech 2026-01-16 Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program
FierceBiotech 2026-01-16 JPM26: Chugai chases new science and name recognition from US biopharma industry
FierceBiotech 2026-01-15 Boston Scientific to snap up thrombectomy specialist Penumbra in deal valued at $14.5B
FierceBiotech 2026-01-15 Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas